Literature DB >> 16760443

Molecular diagnosis of Burkitt's lymphoma.

Sandeep S Dave1, Kai Fu, George W Wright, Lloyd T Lam, Philip Kluin, Evert-Jan Boerma, Timothy C Greiner, Dennis D Weisenburger, Andreas Rosenwald, German Ott, Hans-Konrad Müller-Hermelink, Randy D Gascoyne, Jan Delabie, Lisa M Rimsza, Rita M Braziel, Thomas M Grogan, Elias Campo, Elaine S Jaffe, Bhavana J Dave, Warren Sanger, Martin Bast, Julie M Vose, James O Armitage, Joseph M Connors, Erlend B Smeland, Stein Kvaloy, Harald Holte, Richard I Fisher, Thomas P Miller, Emilio Montserrat, Wyndham H Wilson, Manisha Bahl, Hong Zhao, Liming Yang, John Powell, Richard Simon, Wing C Chan, Louis M Staudt.   

Abstract

BACKGROUND: The distinction between Burkitt's lymphoma and diffuse large-B-cell lymphoma is crucial because these two types of lymphoma require different treatments. We examined whether gene-expression profiling could reliably distinguish Burkitt's lymphoma from diffuse large-B-cell lymphoma.
METHODS: Tumor-biopsy specimens from 303 patients with aggressive lymphomas were profiled for gene expression and were also classified according to morphology, immunohistochemistry, and detection of the t(8;14) c-myc translocation.
RESULTS: A classifier based on gene expression correctly identified all 25 pathologically verified cases of classic Burkitt's lymphoma. Burkitt's lymphoma was readily distinguished from diffuse large-B-cell lymphoma by the high level of expression of c-myc target genes, the expression of a subgroup of germinal-center B-cell genes, and the low level of expression of major-histocompatibility-complex class I genes and nuclear factor-kappaB target genes. Eight specimens with a pathological diagnosis of diffuse large-B-cell lymphoma had the typical gene-expression profile of Burkitt's lymphoma, suggesting they represent cases of Burkitt's lymphoma that are difficult to diagnose by current methods. Among 28 of the patients with a molecular diagnosis of Burkitt's lymphoma, the overall survival was superior among those who had received intensive chemotherapy regimens instead of lower-dose regimens.
CONCLUSIONS: Gene-expression profiling is an accurate, quantitative method for distinguishing Burkitt's lymphoma from diffuse large-B-cell lymphoma. Copyright 2006 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16760443     DOI: 10.1056/NEJMoa055759

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  271 in total

Review 1.  Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification.

Authors:  Elaine S Jaffe; Stefania Pittaluga
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

2.  Transforming the practice of medicine using genomics.

Authors:  Geoffrey S Ginsburg; Geoffrey S Ginsburg; Jeanette J McCarthy
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

Review 3.  NF-κB as a target for oncogenic viruses.

Authors:  Shao-Cong Sun; Ethel Cesarman
Journal:  Curr Top Microbiol Immunol       Date:  2011       Impact factor: 4.291

4.  Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs.

Authors:  Dereje D Jima; Jenny Zhang; Cassandra Jacobs; Kristy L Richards; Cherie H Dunphy; William W L Choi; Wing Yan Au; Gopesh Srivastava; Magdalena B Czader; David A Rizzieri; Anand S Lagoo; Patricia L Lugar; Karen P Mann; Christopher R Flowers; Leon Bernal-Mizrachi; Kikkeri N Naresh; Andrew M Evens; Leo I Gordon; Micah Luftig; Daphne R Friedman; J Brice Weinberg; Michael A Thompson; Javed I Gill; Qingquan Liu; Tam How; Vladimir Grubor; Yuan Gao; Amee Patel; Han Wu; Jun Zhu; Gerard C Blobe; Peter E Lipsky; Amy Chadburn; Sandeep S Dave
Journal:  Blood       Date:  2010-08-23       Impact factor: 22.113

5.  Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.

Authors:  Barbara Pienkowska-Grela; Grzegorz Rymkiewicz; Beata Grygalewicz; Renata Woroniecka; Paulina Krawczyk; Katarzyna Czyz-Domanska; Jan Walewski
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

6.  A novel method of amplification of FFPET-derived RNA enables accurate disease classification with microarrays.

Authors:  P Mickey Williams; Rui Li; Nathalie A Johnson; George Wright; Joe-Don Heath; Randy D Gascoyne
Journal:  J Mol Diagn       Date:  2010-08-05       Impact factor: 5.568

Review 7.  Beyond R-CHOP and the IPI in large-cell lymphoma: molecular markers as an opportunity for stratification.

Authors:  Jason R Westin; Luis E Fayad
Journal:  Curr Hematol Malig Rep       Date:  2009-10       Impact factor: 3.952

8.  Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Authors:  Andrea Sboner; Francesca Demichelis; Stefano Calza; Yudi Pawitan; Sunita R Setlur; Yujin Hoshida; Sven Perner; Hans-Olov Adami; Katja Fall; Lorelei A Mucci; Philip W Kantoff; Meir Stampfer; Swen-Olof Andersson; Eberhard Varenhorst; Jan-Erik Johansson; Mark B Gerstein; Todd R Golub; Mark A Rubin; Ove Andrén
Journal:  BMC Med Genomics       Date:  2010-03-16       Impact factor: 3.063

9.  B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Authors:  Matija Snuderl; Olga K Kolman; Yi-Bin Chen; Jessie J Hsu; Adam M Ackerman; Paola Dal Cin; Judith A Ferry; Nancy Lee Harris; Robert P Hasserjian; Lawrence R Zukerberg; Jeremy S Abramson; Ephraim P Hochberg; Hang Lee; Alfred I Lee; Christiana E Toomey; Aliyah R Sohani
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 10.  Pediatric non-Hodgkin's lymphoma.

Authors:  Thomas G Gross; Amanda M Termuhlen
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.